Dr. Reddy’s Biologics License Application for its proposed biosimilar rituximab candidate DRL_RI has been accepted for a substantive review by the Food and Drug Administration. This closely follows ...
COPENHAGEN, Denmark; May 2, 2024 – Genmab A/S (Nasdaq: GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback